Be a Part of the Fight to End Alzheimer's
Be a Part of the Fight to End Alzheimer's
The millions of people impacted by Alzheimer's disease need your help. Your generosity can help us provide care and support to those facing the challenges of Alzheimer's and advance global research. Please make a gift today.
Donate NowAlzheimer’s Association Looks Ahead to a New Era: Early Detection and Prevention of Cognitive Decline
For decades, Alzheimer’s was typically diagnosed only after memory and thinking problems were already affecting daily life. Now, advances in brain science — including blood‑based biomarkers, digital cognitive tools, imaging and other measures — make it possible to detect the biological changes of Alzheimer’s many years before symptoms begin, opening the door to prevention of cognitive decline, including risk reduction strategies and earlier treatment.
Treatments that slow progression of early Alzheimer’s and offer meaningful benefits have been approved by the FDA and other regulatory agencies around the world. At the same time, compounds designed for individuals who show early biological signs of Alzheimer’s but have no detectable clinical symptoms are now in clinical trials. If these studies are positive, that could quickly change how the disease is managed — enabling intervention before the onset of cognitive impairment and delaying or preventing the onset of memory and thinking problems.
The Spring 2025 Alzheimer’s Association Research Roundtable gathered leaders from academia, medical practice, industry and government to examine where the field stands today on earlier detection and treatment in cognitively unimpaired individuals. They explored a wide range of topics, including:
- Advances in biomarkers to improve early detection and diagnosis.
- The ethical considerations of early biomarker disclosure.
- The impact and effectiveness of treatment interventions at the earliest stages of the disease.
- The clinical importance of delivering early intervention strategies at scale.
- How health systems must prepare to diagnose and treat very early‑stage Alzheimer’s safely, effectively and equitably.
Even more, rigorous studies now show that behavior change matters. Findings from large lifestyle intervention research, especially the U.S. POINTER trial, demonstrate that physical activity, nutritious eating, social engagement and managing cardiovascular risks — delivered with structured guidance and support — can improve cognition and protect brain health in older individuals with risk factors for Alzheimer’s or another dementia.
“Treating Alzheimer’s before symptoms begin mirrors shifts in other diseases, such as heart disease, where prevention and risk management are the standard of care,” said Suzanne E. Schindler, M.D., Ph.D., associate professor of neurology at Washington University School of Medicine, co-chair of the Research Roundtable session and first author on the paper. “Applying the same approach to Alzheimer’s could change aging for millions of people by preserving independence and quality of life for longer.”
Nonetheless, making this transition will be complex.
- Clinicians need better tools and clearer guidelines.
- Patients and families need understandable information and strong support.
- Policymakers must address coverage, regulation and access.
- Researchers require sustained investment to refine early‑stage treatments and determine who benefits most and when to start therapy.
“This moment holds extraordinary promise,” said Christopher Weber, Ph.D., Alzheimer’s Association senior director of global science initiatives. “We now understand more about risk, biology and the ability to slow or prevent cognitive decline than at any time in history. People can act on brain‑healthy choices today, and medications that aim to slow or delay the disease before memory loss begins may soon become available.”
If the health care system, policymakers, scientists and communities prepare together now, the years ahead could bring a future in which fewer people experience cognitive decline, more individuals maintain independence longer and Alzheimer’s is detected and addressed well before it disrupts daily life.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.